Signifor

Active Ingredient(s): Pasireotide Diaspartate
FDA Approved: * December 14, 2012
Pharm Company: * NOVARTIS PHARMS

Pasireotide, sold under the brand name Signifor, is an orphan drug approved in the United States[1] and the European Union[2][3] for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy.[4][5][6] It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin anal... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Signifor .3 mg/ml Subcutaneous Injection
NDC: 0078-0633
Labeler:
Novartis Pharmaceuticals Corporation
Signifor .6 mg/ml Subcutaneous Injection
NDC: 0078-0634
Labeler:
Novartis Pharmaceuticals Corporation
Signifor .9 mg/ml Subcutaneous Injection
NDC: 0078-0635
Labeler:
Novartis Pharmaceuticals Corporation
Signifor .3 mg/ml Subcutaneous Injection
NDC: 55292-131
Labeler:
Recordati Rare Diseases, Inc.
Signifor .6 mg/ml Subcutaneous Injection
NDC: 55292-132
Labeler:
Recordati Rare Diseases, Inc.
Signifor .9 mg/ml Subcutaneous Injection
NDC: 55292-133
Labeler:
Recordati Rare Diseases, Inc.

Related Brands

Drugs with the same active ingredients